AHCO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AdaptHealth Corp (AHCO) is not a strong buy at this moment for a beginner investor with a long-term focus. While there are positive catalysts such as insider and hedge fund buying, as well as recent liquidity optimization, the company's weak financial performance, declining revenue, and net income, coupled with mixed analyst ratings, suggest caution. The technical indicators show a neutral to slightly bullish trend, but the lack of strong proprietary trading signals and the high put-call ratios in options data indicate bearish sentiment. For a long-term investor, it may be better to wait for clearer signs of financial recovery or stronger growth catalysts before committing funds.
The technical indicators show a mixed picture. The MACD is above zero and positively contracting, suggesting a mild bullish momentum. The RSI is neutral at 71.708, and the moving averages indicate a bullish trend (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 12.284, R1: 12.735, S1: 11.834, R2: 13.014, S2: 11.555. However, the stock's recent price movement shows a slight downward trend with a -0.55% regular market change.
Hedge funds have increased their buying by 1321.21% over the last quarter.
Insiders have significantly increased their buying by 20850.77% over the last month.
Reinhart Partners increased its stake by nearly 2 million shares, reflecting confidence in the company.
The company recently closed a $1.1 billion senior secured credit facility to enhance liquidity and optimize its debt structure.
Weak financial performance in 2025/Q4, with revenue down -1.21% YoY, net income down -317.56% YoY, and EPS down -317.65% YoY.
Gross margin dropped significantly to 19.17, down -45.68% YoY.
Mixed analyst ratings, with Deutsche Bank lowering its price target to $9.50 and maintaining a Hold rating.
High options put-call ratios indicate bearish sentiment.
The company's financial performance in 2025/Q4 was weak. Revenue dropped to $846.29M (-1.21% YoY), net income fell to -$100.08M (-317.56% YoY), and EPS dropped to -$0.74 (-317.65% YoY). Gross margin also declined significantly to 19.17 (-45.68% YoY).
Analyst ratings are mixed. Truist raised its price target to $14 from $13 and maintains a Buy rating, citing strong demand trends and favorable reimbursement policies. Canaccord lowered its price target to $14 from $15 but maintains a Buy rating, highlighting operational improvements and free cash flow generation. Deutsche Bank lowered its price target to $9.50 and maintains a Hold rating, reflecting concerns over recent financial shortfalls and legal settlements.
